Good afternoon. My name is Emma, and I will be your conference operator today. At this time, I would like to welcome everyone to the Phreesia Fiscal First Quarter 2023 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press the star one. Thank you. Balaji Gandhi, you may begin your conference.
Thank you, operator. Welcome to Phreesia's Earnings Conference Call for the fiscal first quarter of 2023, which ended on April 30, 2022. Joining me on today's call are Chaim Indig, our Chief Executive Officer and Co-founder, and Randy Rasmussen, our Chief Financial Officer. A complete discussion of our results can be found in our earnings press release and in our related Form 8-K submission to the SEC, including our quarterly stakeholder letter, both issued after the markets closed today. These documents are available on the investor relations section of our website at ir.phreesia.com. As a reminder, today's call is being recorded and a replay will be available on our investor relations website at ir.phreesia.com following the conclusion of the call.
During today's call, we may make forward-looking statements, including statements regarding trends, our anticipated growth, our strategies, predictions about our industry, and the anticipated performance of our business, including our outlook regarding future financial results. Forward-looking statements are subject to various risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from those described in our forward-looking statements. Such risks are described more fully in our earnings press release, our stakeholder letter, and our risk factors included in our SEC filings, including in our quarterly report on Form 10-Q that will be filed with the SEC tomorrow. The forward-looking statements made on this call will be based on our current views and expectations and speak only as of the date on which the statements are made.
We undertake no obligation to update and expressly disclaim the obligation to update these forward-looking statements to reflect events or circumstances after the date of this call or to reflect new information or the occurrence of unanticipated events. We may also refer to certain financial measures not in accordance with generally accepted accounting principles in order to provide additional information to investors. These non-GAAP measures should be considered in addition to and not as a substitute for or an isolation from our GAAP results. A reconciliation of GAAP to non-GAAP results may be found in our earnings release and stakeholder letter, which were furnished with our Form 8-K filed after the market closed today with the SEC and may also be found on our investor relations website at ir.phreesia.com.
With that out of the way, let me hit a couple of the highlights from the quarter in case you have not had a chance to review the earnings release and the quarterly letter. First, our investments continue to drive strong growth in our network. In the first quarter, average healthcare services clients were up 33% year-over-year.
Second, payment processing revenue in the quarter reflected patient utilization trends that were slightly below our expectations based on our prior experience. We think this trend could persist in the remainder of the year, which is the main reason we're maintaining our revenue outlook for the year at $271 million-$275 million. This range implies growth of 27%-29% year-over-year.
Third, life sciences growth was up a strong 51% year over year, and revenue was down a slight $563,000 sequentially from Q4. This sequential trend is consistent with historical periods where you see Q4 to Q1 flat to down due to seasonality.
We continue to be pleased with our team's performance in this area, and we expected this team's continued performance to contribute to our overall growth in fiscal 2023. The last highlight, we began to see strong operating leverage across all of our investments over the past year, which is why we've taken up the adjusted EBITDA outlook for the year to a range of negative $126 million to negative $122 million, which is up from our prior outlook of negative $154 million to negative $149 million.
Before jumping into the Q&A session, let me hand it over to our CEO, Chaim Indig.
Thank you, Balaji, and good evening, everyone. Thanks for participating in our fiscal first quarter earnings call. I'm very proud of our team for their commitment to our clients and their mission. Internally, we think of ourselves as operators who provide an amazing experience across over 100 million patient visits a year that impacts the entire healthcare ecosystem. We're able to do this because of our outstanding and committed product and engineering organization. I want to say thank you to all of them.
For 17 years, we have felt strongly that if we build great product and put it in the hands of our clients, we will produce a great return, and they will remain happy clients.
It's been wonderful to see the net effect of our product and engineering teams working with our go-to-market teams, and we know it will continue to pay dividends for all of our stakeholders in the years to come.
I'm sure we'll get deeper into the highlights Balaji touched on as well as other topics. Let me add, it's been great to be out there meeting in person again. I've had the opportunity to meet with Phreesia colleagues, clients, and shareholders in person over the past few months, and it really does make a difference. We look forward to seeing many of you over the summer and the months that follow. Operator, I think we can open up for Q&A now.
Thank you.
Thank you.
At this time, I would like to remind everyone, in order to ask a question, press star then the number one on your telephone keypad. Your first question today comes from the line of Anne Samuel with JP Morgan. Your line is now open.
Hi, guys. Thanks for the question, and congrats on the strong logo growth this quarter. I was hoping maybe you could touch on some of the dynamics around revenue per provider client, and what caused the decline there.
Annie, just so we're clear, you're talking about total healthcare services revenue?
Yes. Mm-hmm.
The revenue per client, you're talking about the $19.2?
The nine- $19.2 . [crosstalk]
Yeah, the revenue per provider-client.
Yes.
Oh, for the year-over-year.
Year-over-year.
Yeah. I think from the perspective of, you know, we've talked about this in the past where, you know, we're doing a big land and expand as we get additional clients. Often they come in and, you know, the first dollar of revenue comes in and we expand into other areas. If you look at it quarter-over-quarter, there was nice expansion on the revenue per client. I think, you know, also in the-
Okay, thank you.
In the table, I think we also show, too, if you look at the subscription per provider client, it's been consistent at $11,500 , you know, for several quarters now. You know, we see that continuing to go at that level or higher as we move into the future quarters.
Okay.
Annie, I think I was just gonna add. I think Randy brought up a good point, which is, you know, we've talked a lot to a lot of people about those two lines independently. If you actually look at subscription per client and payments per client, you sort of see that story that Randy talked about a little bit better.
Okay. Very helpful. You know, I was hoping maybe you could touch on EBITDA. You know, you raised your EBITDA outlook by more than you beat today. You've now got an improved timeline for profitability. Was hoping maybe you could talk about, you know, what some of those profitability levers are, you know, coming in better than you expected.
Yes. I think, you know, we made some significant investments in fiscal 2022, and I think G&A is a really good example where we made some investments. We went live with a new ERP system last year, and we're seeing the benefits of that this year, and I think the leverage on those investments is accelerated versus what our expectation is. I think there's also, you know, when we did guidance for the year a couple months ago, there's still some questions about Ukraine and some of our third-party providers, and I think we have more clarity there. That's also helped us, you know, revise our expectations for the year.
Great. Just one housekeeping question. I didn't see it in the letter. I was hoping you could provide how many SDRs you have now.
It's the same as it was at year-end. It's at 232.
Great. Thanks very much, guys.
Your next question comes from the line of Ryan Daniels with William Blair. Your line is now open.
Yeah, guys. Congrats on the strong start to the fiscal year. Thanks for the questions. Curious what you're seeing in regards to patient utilization trends. I know you mentioned in your prepared comments it was lower than anticipated. Is that more a dynamic of COVID-related issues with patients coming in, or is it some of the challenges your client base is seeing in workforce and, you know, just retaining or maintaining productivity of the healthcare workers?
Hey, Ryan, this is Chaim Indig. You know, I think we're hearing it's a mixture of, you know, COVID, you know, hitting their staff and obviously their patients, but also just like staffing levels. I think we're seeing that as a combination throughout. I don't think there's any one answer, and I think we've seen it fluctuate throughout the entire healthcare ecosystem.
Okay. That's helpful.
It's been tough for our providers. We're just trying to make sure that they, we're providing them all the tools so they can treat the patients they will, that need to be treated.
Yeah, absolutely. I guess my follow-up, love to get an update on your offering for social determinants of health. You specifically called that out in some detail in your letter. It's a topic we focused on a lot lately, and I think regulators and payers and providers are all focused on it. I'm curious what kind of traction you're seeing there and what maybe future investments or growth outlook for that specific product offering is. Thank you.
Yeah. Well, you know, Ryan, I'm glad you brought that up. Social determinants of health are not just impacting people's health and their wellness and how they get treated, but they're also things that people, what we found in working with providers, they often have a hard time bringing up that they want to address, whether it's food insecurity, or domestic violence, or having a safe place to sleep. What we really focused on is not monetizing social determinants of health, but empowering our providers to figure out who needs help and how they need help, and making sure we do it at scale in a non-judgmental way. That's just an important part of doing the right thing. You know, I don't know what the economic benefit of social determinants are, Ryan, but I know it's just the right thing to do.
People go into healthcare to do the right thing, and we will keep doing that as an organization.
Okay. Appreciate that. Chaim, congrats on the announcements on your best places to work. I know culture is important for you, so kudos on that. Thanks.
It is. The only reason we got this amazing company is because this amazing group of people that are committed, and I'm really proud to work with them.
Your next question comes from the line of Jessica Tassan with Piper Sandler. Your line is now open.
Hi. Thank you so much for taking the question, and congrats on the strong EBITDA. So I just had a couple questions on the Connect offering. First off, I think we know patients are typically engaging with the intake management interface and self-scheduling, but just curious, who is primarily interfacing with Connect? Is it the patient or the practice admin or the provider themselves? And then just if it's the provider, where does Connect kind of sit in the context of the EHR and the provider's practice management interfaces?
Oh, Jess, that was like a very long question. I think I got it.
I'll paraphrase.
All right. You think Connect is awesome like we do. Okay? That's sort of what I heard.
Got that right. Yeah.
All right. You're trying to figure out who uses Connect. Over a long period of time, we do envision Connect really being tied to the patient, right? Because it's how they book their appointment. Right now, the vast majority of the connections with Connect are between the provider's staff and the other provider's staff. Did I answer the question? Very rarely the actual provider themselves.
Got it. The vision is eventually, though, the patient might be able to access that through the self-scheduling or intake management interface.
We sure hope that happens, but we are [crosstalk] very focused on the patient.
Okay. Got it. Just, are the provider clients who are potentially exclusively participating in the Connect referral network included in the total provider count, or does the provider have to be a Phreesia intake management and scheduling customer in order to have access?
For a client to be counted, you gotta pay us money. If they're a client, they're a client. Am I right, Randy?
Yeah, that's correct. Yeah. We count them as soon as the first dollar comes in.
That's helpful. Just finally, in terms of revenue recognition and seasonality of the Connect offering, where is that revenue recognized? I would imagine its strength is correlated to the sequential recovery and payment volumes, but just wanna confirm if that's true.
No, I don't think there's a correlation between that and payment volume right now.
From a revenue perspective, it's in the subscription number.
Got it. All right. Thanks. That's helpful.
Your next question comes from the line of John Ransom with Raymond James. Your line is now open.
Hey, good afternoon, team. This is sort of analyst one-on-one, but a couple of nits. First of all, is there anything to call out in sort of the rhythm of smaller clients versus larger clients in your customer growth year-over-year? And then secondly, if we think about the rest of the fiscal year, how should we think about the components, the three revenue components? I know you said life science is seasonal, but is there anything to think about in terms of how the three interplay to be the same or different from that? Thanks.
I think I'll answer the first part, which is how do we think about size of client. I think I've said this a couple times, but I appreciate you making me say it again. We care about all clients, big and small. We sell to them all.
Right. Okay.
You know, as long as you need help, we'll be there to help you. I think we've historically seen the plethora of that happen across our growth in our network. Then what was the other question?
Timing of revenue.
Oh. I don't know how that's going to be .
I mean, I think, you know, as mentioned in the letter, I mean, I think in the life science business, you know, typically, because of the way that the advertising budgets roll year-over-year, you know, moving from Q4 to Q1 is typically flat or slightly down. That builds during the year. You know, I think, you know, payments also have some seasonality to it based on, you know, the patient responsibility, which is typically paid earlier in our year. You know, I would think the patterns are similar to, you know, what we've seen in other years.
John, you know, just I think, you know, in terms of what we communicated back at the end of March for the year, I think the only thing, you know, to consider is that the reason we're keeping the guidance where it is is 'cause of this, you know, the payments trends that we saw in the first quarter, but otherwise nothing different from what we saw 60 days ago.
If I could, like, reset that first question. I didn't. I wasn't asking, like, who's important to you. I just said the customer adds that you had, was there anything to call out between the mix of larger versus smaller clients in that change? I didn't ask that at all. I apologize.
No. Oh, okay. Good. I thought you were trying to see if we, like, liked one more than the other. Right?
No.
The answer is no, John. We're not seeing any material shift in the mix.
Thank you.
Thank you. Did I answer it the second time?
Much better.
Okay. I'm working really hard. This is like I'm almost 3 years in. Maybe one day I'll be good at this.
I know you are. Nobody questions that. Thank you.
Your next question comes from the line of Joe Vruwink with Baird. Your line is now open.
Great. Hi, everyone. A question on going back to subscription revenue per client and the trend there. It makes sense just given the magnitude that's been onboarded new over the past really five quarters now that you kind of expect a sequentially stable trend. I guess it also follows that we'll reach a point where we should start to expect some expansions out of this cohort. Any updated guidance, yeah, I think it's been a couple of years maybe since dollar-based net retention figures were provided, but maybe how that should look as we think about kind of a mature customer base that is looking to grow.
I mean, I think, you know, last quarter we talked about, you know, the low levels of churn that our customer base is, you know, very sticky. You know, I think we continue to have success in upsell and cross-sell. We haven't given, you know, net revenue retention numbers since the IPO, but, you know, our strategy is still land and expand, and we still feel, you know, that that's going very well for us.
You know, I think the other thing, Joe, is you could look at where we were when we went public 3 years ago on subscription revenue per client and look at where we are at this quarter. It's grown meaningfully. It's just sort of got that step function aspect to it. In terms of the opportunity, we still think the TAM is $126,000 per client on average, and that's all types of clients. You know, that's. I think it's close to 3 x in terms of the opportunity. We still feel good about that.
Okay. Thanks. That helps. Last one for me. In terms of the sequencing of maybe quarterly capex investments for the remainder of the year, you know, obviously the guide kind of entails just annualizing the 1Q EBITDA. Is the right way to think of it, you know, kind of stable with 1Q OpEx, stable with 1Q cost of sales, or is there anything, you know, timing related where things are maybe a bit lower here in 1Q, and so sequentially there's still a bit of a step-up to go?
Yeah. You know, Randy, maybe you want to talk about the gross margins, how we think about that aspect.
Yeah. I mean, I think if you look at the gross margins, we expect those to expand in the second half of the year. Then, you know, I think there are certain expenditures that do have timing, you know, such as corporate events or marketing. You know, also, you know, we have internally capitalized software, so sometimes that fluctuates from quarter to quarter. Those things all affect the timing.
Okay. That's great. Thank you.
Your next question comes from the line of Glen Santangelo with Jefferies. Your line is now open.
Oh, yeah. Thanks, and good evening, guys. Hey, I just wanted to follow up on that sequential EBITDA question previously. You know, if we take your annual revenue guidance, it kind of implies about 6% sort of sequential growth here for the remaining three quarters. I guess the assumption is that your OpEx is gonna grow maybe even faster than that if you're talking about some gross margin expansion in the back half of the year. It was my understanding, and I just wanted to get an update, Chaim, on the hiring needs of the business. It sounds like we were largely through the investment phase that we talked about on the previous, you know, two or three calls.
I was wondering if you could update us on that investment phase and how we should think about, you know, the operating expenses on a sequential basis from here relative to revenue growth?
There's a lot. All right. Let me try to unpack that. Are we through the investment phase? The answer is no. Like, we're continuing to invest. We're just now starting to see really good leverage off these amazing people that we've brought on board, and they're doing amazing work. Like, we're continuously investing in them and our clients. But will we see the ramp of the number of people that we bring on the organization in the near term at the same pace that we had? I don't think that's the plan. I think. Did I answer the question?
Yeah. I mean, I guess you did, right? I mean, but, you know, what we're looking at, right, is a loss this quarter of about $31 million in EBITDA, right? You're guiding basically, you know, as the previous question kind of implied, right, $125 million for the year. That would imply, you know, a negative $30 million in EBITDA in each of the next three quarters, roughly speaking. It kinda suggests that expenses are growing essentially in line with revenue. You know, and I get it, we don't have all the details. I just wanna make sure we're sort of thinking about that right.
Yeah.
Yeah, I think Randy talked to Glen about, like, timing of certain things. You know, maybe we could, you know, try to be helpful in following up in terms of the cadence of this. It's a pretty tight range, you know, as it is, and, you know, we obviously expect to get better as time goes on. Yeah. Like, for example, I mean, the capitalized software is just, you know, allocation of cash flows. Is it investing or is it in operating? And that can affect the EBITDA numbers. I think we're just thoughtful about, you know, how do we forecast that because it's somewhat based on the investments and what the engineering teams are working on.
Yeah. Perfect. The last question, a lot of people are always asking about the balance sheet and the cash needs of the business and, you know, if you look at sort of your cash balance at this point, you're at, let's call it, $269, I think, right? You know, it's taking your EBITDA guidance of, call it, minus $125, right? That's almost. I don't wanna call it half the cash, but rough numbers, it's kinda half the cash. Based on your fiscal 2025 guidance, I think you're sort of implying that you will reach profitability in fiscal 2025. Is that in one specific quarter in fiscal 2025?
How should we think about the cash needs of the business relative to, I'll call it the three-year fiscal plan you've laid out in terms of revenue, and profitability in fiscal 2025? Thanks.
Yeah. No, that's a good question. You know, we feel confident that the current cash balance and the line of credit is sufficient to finance our plan to achieve the fiscal 2025 targets. You know, that's, you know, if you look at the goal of being profitable in 2025, I mean, that implies that, you know, revenues grow at a CAGR of 28% and that our expenses will grow somewhere, you know, 10%-11% or less to achieve that profitability.
Okay. Very helpful. Thank you.
Your next question comes from the line of Richard Close with Canaccord Genuity. Your line is now open.
Yeah. Thanks for taking the questions. Congratulations. Maybe a follow-up to, I think it was, forget whose question it was, sorry. There was a HFMA survey out there that said something like 35% of health systems have vacancies on the front staff and scheduling and registrars and whatnot. I was just curious, you know, how much do you think that is driving demand for your products? And then when you guys go to market, how important is it showing that Phreesia's enhancing productivity, maybe they don't need to fill those vacancies going forward? Just any thoughts there.
All right. Richard, I don't know whose question you're following up on, but why don't I give, like, a random statistic that I think Karen told me, who runs our marketing organization. Our SDRs last year made 2 million phone calls into healthcare organizations. I think the reason we saw the uptick in clients is not just because they have a need, but we got in front of them, and we had a proposition.
We had a great product that provided a phenomenal amount of value. You know, whether it's changing nature of the healthcare ecosystem, whether it's demand changes, you know, the reason I think we're doing well is because we got a great product, and we get it in front of prospects in a very thoughtful, efficient way, and we do it with an amazing group of people.
I don't think, you know, Evan often says, like, "Fish aren't jumping in our boat, right? We know where to fish.
Okay, that's helpful. Randy, maybe, with respect to fiscal 2025, I think you said you have multiple levers there to reach the targets. I wonder if you could just dive in a little bit deeper, on specifically what you're meaning there.
Yeah. I mean, I think I talked about the investments that we made. I think G&A is a good example where, you know, we grew that organization to support a public company, and we're at that level now. I think, you know, as we continue to become more productive, we realize the benefit of that. I think also from, you know, a multi-year perspective, it's like we haven't invested. You know, we're a remote organization.
We haven't invested in the corporate headquarters. We haven't done really large transformation, you know, acquisitions. That enables us to be flexible and not have huge fixed costs in our cost structure. All of that helps us lever towards profitability in 2025.
Okay. Final question would be on payment facilitation that ticked up a little bit. Can you just go over that number in terms of how we should think about that the rest of the year? Is that just, you know, basically the mix of new clients that have come on over the last several quarters that drove that up? Just thoughts around that would be helpful.
Are you talking about the PayFac percentage, the 80%?
Yeah. Correct.
that went from something? I mean, I think if you look at the last couple quarters, it's actually been fairly stable. I think, you know, it depends on client mix and if they take our payments or not. You know, of course, some of the larger health systems may have treasury functions where, you know, we're unlikely to win that business. But we try with every new client to win that business, and it's been fairly stable. I don't expect that number to move a whole lot, you know, in the next couple quarters.
Okay. Thanks.
Your next question comes from the line of Ryan MacDonald with Needham & Company. Your line is now open.
Hi, thanks for taking my questions, and congrats on the great quarter. Chaim, maybe the first one for you. You know, in the stakeholder letter, you talked about the, you know, the research you're doing in-house and the report really focusing on sort of the misalignment between what patients want and what vendors currently have. I think one of the examples was around self-scheduling. Just curious, you know, as you kind of have that report and kind of go out to existing customers, how do you try to drive greater adoption of those additional modules around the self-scheduling, to expand sort of your penetration or wallet share with those customers and maybe close that gap of misalignment?
Yeah. I think what was very telling about this, and we really were pretty excited about. I, like, while you were talking, I'm sorry if I was shuffling. I was, like, moving around the paper so I could look at the report, which is out here. It's a great report, by the way. This is sort of a lens into how we think about building and where we make investments in product and when we talk to clients, also explaining to them what their patients are telling them, right? Sometimes I think there is a push-pull with what people think that they want based on what vendors are telling them versus what patients are telling them are important to them.
You know, what we found is having data has been very, very powerful in being able to best represent the needs of their organizations and how we fit in them. It's worked really, really well for us over the last 17 years, and we continue to invest in that. We hope this is a lens into how we think about our product roadmap and our investments long term.
That's really helpful.
Yeah.
Maybe in terms of my follow-up, on the life sciences business, I understand sort of a return to normal sequential seasonality before fourth quarter and first quarter. But as we think about, you know, your conversations with customers and what digital marketing budgets look like for this year, are you seeing any changes or maybe a sort of a comeback down to normal marketing sort of campaign trends post-pandemic as you think about this year? I think you used the term in the shareholder letter that you continue to refine your campaigns. You know, are you seeing any increased scrutiny around sort of the efficacy of some of the campaigns that you're pursuing with your customers? Thanks.
Yeah. I think we've always assumed that there should be a ton of scrutiny around the things we do and the value they provide. That is, you know, why almost all of them have, you know, third-party ROI analysis, why we provide regular reporting to our clients and why we work with them so closely. I would say that I don't wanna speak for all of our clients. I don't think there is a rush to return back to paper and pamphlets and, you know, I think everyone's questioning how many more ads you could put on network TV because most people are just streaming. I do think we've seen a real change in behavior.
Now that, you know, we've gotten a lot of these clients using us at scale, we're starting to see the net effects of them seeing their results, and it's been very promising.
Your next question comes from the line of Stephanie Davis with SVB. Your line is now open.
Hey, guys. Thank you for taking my questions and congrats on the client ads. Do you guys have exposure to the overall patient visit market? How should we think about your volume exposure to more discretionary areas of medical, such as derma, dental, that could be impacted by a potential recession or inflationary pressures?
We don't really have too much data. I don't think we have that much discretionary. Stephanie, like, most of our large derm groups, I'd say are more focused on medical derm than they are on cosmetic. I'd say our dental footprint is almost nonexistent outside of health systems, our larger clients and FQHCs that have some dental practices. We are nominally focused in things that are elective at this point. If that changes, we'll probably communicate that to our investors.
Helpful. Thank you. You guys touched on this a little bit on the margin outlook, but I was surprised to see that your adjusted sales and marketing was flattish quarter-over-quarter. Could you help us tease out how much of that was efficiencies or how much of that was an end to the Salesforce build-out?
I think most of it was just efficiencies. Like, I don't think we're communicating the end of our Salesforce build-out. I think it's more along the lines of, you know, we have a phenomenal group of operators who are shareholders and pay attention to where they spend money, and that's why we trust them. You know, they look at how we spend money, and they spend it and, you know, where the best place to allocate it for a return. You know, it's what happens when you have amazing people, and you trust them. They do the right things.
Is it wrong to assume we flatline that number for the rest of the year?
I don't think we're saying whether we flatline it or not. I think, but we're fairly comfortable with our outlook and our revenue guidance. You know, eventually something's gotta give. Like, there's a pie, and the pie, we can only cut it so many ways. Yeah, I think Randy's comment around, you know, expenses growing a lot lower.
Yeah, I think, you know, longer term, right, they have to grow in, you know, in a, you know, 10%-11% range so.
All right. Helpful. Thank you, guys.
Thank you.
Your next question comes from the line of Joe Goodwin with JMP Securities. Your line is now open.
Great. Thank you so much for taking my questions. Can you just talk about the pipeline for enterprise clients or, you know, larger health systems and if you've been making any adjustments to go-to-market motion, you know, for these larger customers?
We don't tend to comment on the pipeline. I think our go-to-market motion for the enterprise has been fairly consistent, Joe, for quite some time, which is build amazing product, show that it works, land, you know, when you land them, and then continuously add value, add more value, grow the account, and then do it again over and over again and never ever stop. Do that for our large clients and small ones, and treat all of the clients with the way they should be treated, which is unbelievably well because they take care of all of our families. I think that's the way we think about all of our enterprise clients and our small clients.
Got it. Okay, thank you for that. I guess, Chaim, you know, are you seeing clients land with more solutions, from the get-go? You know, are you seeing any changes into what solutions these new clients are actually landing with?
Yeah. What I am hearing a lot from our team is that we're getting more clients landing with different things as opposed to just intake. Right? Like we're landing with different products at our clients, and that's great to see, especially as our sales organization has gotten more comfortable, and has had more reference accounts and more successes with different product offerings. Yeah, we've seen the plethora. I still think like, you know, we're generally known for intake, you know, because that's what we've been doing for so long. That's still the vast majority of what we land with. It's a great product, so.
Great. Thank you.
Your next question comes from the line of Jack Wallace with Guggenheim. Your line is now open.
Hey, thanks for taking my questions and great job on the quarter. To further the analogy from earlier, you know, are there any, you know, ponds that are more well-stocked than others where you've had more or less success fishing, you know? Not necessarily the client size, but in some of the specialty areas or geographic regions. Thanks.
Yeah, no, I don't think there has been any area. I'd say what it really comes down to is just work, right? Like, we just made a lot of phone calls and sent a lot of emails and, you know, tried to find people who had problems that we could help solve. I think what we continuously find is that people are so busy, you know, trying to take care of their patients and run their ERs and, you know, deal with their, you know, their like, that they're not necessarily looking for solutions. We're out now, getting out in front of them to make sure that we can deliver solutions to just add that tremendous value, and it's been working.
Like this past quarter is another testament as we've had for many years that, you know, it's usually just hard work.
Got you. That's helpful. You know, on that front, you know, the efficiencies of the sales and marketing team. You know, is there a pull back in some of the travel and entertainment that would be, you know, say, a pre-COVID level?
Obviously, we hired a ton of people over the last year plus, and now, you know, as we're seeing the expense line level out a little bit, more efficiency on a, let's call it a per rep basis. You know, is there a baseline level of or lower level of T&E required to go make the incremental sale? You know, that's gonna be carryover going forward. Are we still seeing, you know, some of that potentially coming back in the back half of the year?
Yeah. I think we let our people decide what's best, you know, travel. I don't say we're big on the entertainment front, so it's more just travel. Is that fair, Randy?
Yeah. Yeah, we don't spend a lot on entertainment.
No. It's mostly just travel in Q2 and travel to see each other because I think that is important. You know, as much as we can, we try to make sure that we get together in person where it's, like, cost-effective and reasonable. You know, I think it mostly has to do with, like, as I said earlier to Stephanie's question, which is just making sure that we empower our team to make smart decisions. I mean, if you hire really good people and you empower them to make smart decisions, more often than not, it works out well for all of us.
Gotcha. That's helpful. Thank you.
Cheers.
There are no further questions at this time. I would like to turn the call back over to Chaim Indig.
All right. Balaji says I have to say really nice things to wrap up the call, so thank you everyone for participating, and we look forward to talking to everyone in a couple months. If you have any questions or comments, investors@phreesia.com is a great place to reach us. If you don't know Balaji's number. All right. Have a great one, everyone.
This concludes today's conference call. Thank you for attending. You may now disconnect.